5 Here, we describe a case of aggressive CAR+ T-cell lymphoma and investigate its lymphomagenesis. A 60-year-old man received the diagnosis of primary central nervous system lymphoma (PCNSL ...

Both agreed that there have been no trials directly comparing a BsAb therapy vs CAR T cells, so there is no definitive answer, and Landsburg was reluctant to take a hard line on reserving BsAbs until ...

Lymphoma, a cancer of the immune system, is silently ravaging the health of Black men across America. This insidious disease, ...

July 22, 2024 — The effectiveness of CAR T cell therapy against a variety of cancers, including solid tumors, could be boosted greatly by using CRISPR-Cas9 technology to knock out the gene for ...

"CAR T cells work well against hematological cancers like leukemia and lymphoma, but they're really not effective for solid tumors like ... ovarian cancer and suggest new avenues to improve the ...

Lymphoma is a type of cancer that affects the lymphatic system, a vital part of the immune system. For individuals facing ...

Survival rates for aggressive lymphomas ... weeks as a patient's T cells, which normally help fight off infections, are collected and genetically engineered to target lymphoma.

Burkitt lymphoma, typically found in children, is a rare, but aggressive type of non-Hodgkin lymphoma, a cancer that starts in special white blood cells called lymphocytes (which help defend the ...

adult T-cell leukemia–lymphoma (ATL) is first divided into two groups: indolent (i.e., smoldering or chronic type) or aggressive (i.e., acute or lymphoma type). The prognosis of indolent ATL is ...

AbbVie (NYSE: ABBV), today announced that nine (9) provinces have provided accelerated public coverage of EPKINLY™. EPKINLY is a treatment for adult patients with Relapsed or Refractory diffuse large ...

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede ...